Relay Therapeutics (RLAY) Non Operating Income (2019 - 2026)
Relay Therapeutics (RLAY) reported Non Operating Income of $5.3 million for Q1 2026, up 58777.78% year-over-year from N/an in Q1 2025, and up 17563.33% quarter-over-quarter from $30000.0 in Q4 2025.
Relay Therapeutics (RLAY) Non Operating Income (2019 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 8 years of Non Operating Income data on file, last reported at $5.3 million in Q1 2026.
- Non Operating Income for Q1 2026 came in at $5.3 million, up 58777.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.9 million (down 57.59% YoY), and the FY2025 annual result was -$776000.0, down 102.23% from the prior year.
- Non Operating Income climbed to $5.3 million in Q1 2026 per RLAY's latest filing, from $30000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $9.0 million in Q1 2024 and troughed at -$633000.0 in Q2 2025.
- A 5-year average of $4.0 million and a median of $5.3 million in 2026 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income slumped 128.57% in 2023, then jumped 413300.0% in 2024.
- A 5-year view of Non Operating Income shows it stood at $5.3 million in 2022, then jumped by 62.7% to $8.7 million in 2023, then rose by 3.15% to $9.0 million in 2024, then plunged by 99.67% to $30000.0 in 2025, then jumped by 17563.33% to $5.3 million in 2026.
- Business Quant data shows RLAY's Non Operating Income at $5.3 million in Q1 2026, $30000.0 in Q4 2025, and $6.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | Relay Therapeutics | 2.86 Bn | 2.86 Bn | - | 5.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.30 Mn |
| Dec 31, 2025 | 30,000.00 |
| Sep 30, 2025 | 6.24 Mn |
| Jun 30, 2025 | -633,000.00 |
| Mar 31, 2025 | 9,000.00 |
| Dec 31, 2024 | 8.98 Mn |
| Sep 30, 2024 | 8.26 Mn |
| Jun 30, 2024 | 8.55 Mn |
| Mar 31, 2024 | 8.98 Mn |
| Dec 31, 2023 | 8.70 Mn |
| Sep 30, 2023 | -2,000.00 |
| Jun 30, 2023 | -14,000.00 |
| Mar 31, 2023 | 6.94 Mn |
| Dec 31, 2022 | 5.35 Mn |
| Sep 30, 2022 | 7,000.00 |
| Jun 30, 2022 | 1.02 Mn |
| Mar 31, 2022 | 675,000.00 |
| Dec 31, 2021 | 830,000.00 |
| Sep 30, 2021 | 157,000.00 |
| Jun 30, 2021 | 1,000.00 |